Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
The hospital through its network performs more than 10,000 joint replacement surgeries annually
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively
This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
The clinical research organisation located in Hyderabad is a USFDA inspected facility
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
Subscribe To Our Newsletter & Stay Updated
